Professor Joost Meijers is manager of the Plasma Proteins department of the Research Division of Sanquin. He started his career at Utrecht University, became professor at the AMC Amsterdam and joined Sanquin in 2014. Besides doing research he committed himself to teaching and was involved in numerous committees in the field of hemostasis and fibrinolysis. He is currently chairman of the ISTH SSC Subcommittee on Factor XI and the Contact System, Secretary/Treasurer of the International Society on Fibrinolysis and Proteolysis, and is member of the Executive Board of the Dutch Thrombosis Foundation.
Theo Rispens is group leader at the department of Immunopathology Research. His research topics cover all aspects of antibodies, from structure-function analysis of IVIg to regulation of antibody production. This includes immunogenicity of biologicals.
Marieke von Lindern is head of the department of Hematopoiesis. Her department investigates the process by which mature peripheral blood cells are formed from the hematopoietic stem cell (HSC). Important topics are aging of stem cells and the culture and maturation of various blood cell types from progenitor cells, isolated from peripheral blood.
Robin van Bruggen started his career at Sanquin in 1998 as a PhD student. After his PhD and two post-doc projects, he is currently the group leader of the Red Blood Cell research group at the Laboratory of Blood Transfusion Technology.
Paula Ypma is a hematologist in The HagaZiekenhuis in The Hague for over ten years now. Although, during her study Ypma was never much involved in research, the drive to be part of a scientific study was still there. So, since two years now, she spends one day a week on research; a clinical trial study performed by Sanquin.
Jean-Louis Kerkhoffs is a hematologist in The HagaZiekenhuis in The Hague and a senior researcher at the Department of Clinical Transfusion Research at Sanquin as from 2004. In May 2012 he finished his PhD ‘Efficacy of platelet transfusions’. He is a specialist in the areas of platelet research, sickle cell disease and therapeutic aphaeresis.